Farmas USA

ADXS lo bueno de este +8% es que reafirma mi entrada en el valor ...a pesar de que ayer las solté ...tomo nota para volver a entrar si vuelven a caer ...aunque espero que no , por los que están dentro...😉

SGYP ...veo que sigue el plan , sin descartar nada ...lleva un +_65% de pérdida en las últimas 52 semanas , y bajo mi punto de vista , está a punto de recuperar , solo le hace falta cambiar la tendencia , que no es poco ....🤔

Plantéate cenar en horario europeo a eso de las 18.30 h de la tarde. Es mucho más sano y así coincides con los usanos. Claro que para eso tendrás que comer a medio día.

EXEL

A mí no me ha llegado comunicado ni lo veo en el sitio de la empresa, pero dicen por ahí:

$212M Revenue, .37 EPS, huge beat y new partnership with Invenra

Edito: ahora sí

Exelixis (NASDAQ: EXEL): Q1 EPS of $0.37 beats by $0.21.

Revenue of $212.35M (+162.5% Y/Y) beats by $69.59M.

Shares +5.82%. Oh, yeah!

https://seekingalpha.com/news/3351622-exelixis-beats-0_21-beats-revenue

https://seekingalpha.com/pr/17150201-exelixis-announces-first-quarter-2018-financial-results-provides-corporate-update

EXEL

Exelixis and Invenra Enter Into Collaboration to Discover and Develop Novel Biologics to Treat Cancer

– Companies will partner to advance multispecific antibodies in up to seven discrete projects, including one program against an undisclosed target currently in lead

Exelixis and Invenra will collaborate to discover and develop multispecific antibodies through the use of Invenra’s B-Body™ technology platform, which enables high-throughput discovery, functional screening, and in vitro and in vivo preclinical characterization of promising therapeutic candidates. Invenra will be responsible for antibody lead discovery and generation. Exelixis will lead investigational new drug (IND)-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, as well as future regulatory and commercialization activities.

Under the collaboration agreement, Exelixis will receive an exclusive, worldwide license to one preclinical asset, and Exelixis and Invenra intend to pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs. In consideration for the exclusive worldwide license and other rights contained in the collaboration agreement, Exelixis will pay Invenra an upfront payment of $2.0 million plus $2.0 million at initiation of each discovery project. Invenra is eligible to receive payments of up to $131.5 million based on the achievement of specific pre-clinical, clinical development and regulatory milestones for any product containing a lead preclinical asset in the first indication. Upon successful commercialization of a product, Invenra is eligible to receive global milestone payments up to $325 million, if certain sales thresholds are achieved as well as single digit tiered royalties on net sales of the approved product.

https://www.businesswire.com/news/home/20180502006613/en/Exelixis-Invenra-Enter-Collaboration-Discover-Develop-Biologics

Hostiazo AKAO

hoy rompe ese canal bajista :)

enhorabuena por ese aguante

EXEL

KERX

teoricamente ahi tenemos un canal de consolidacion antes de reanudar tendencia, ya veremos. ER hoy

NVAX, ER el 9

Offtopic

Por favor, si alguien consigue información del annual meeting shareholders de AMD, que lo ponga por aquí. En la web no hay nada colgado, y en ST nadie sabe nada. En teoría fue ayer.